Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma

Figure 1 Flow diagram of patient selection. HCC: Hepatocellular carcinoma; MRI: Magnetic resonance imaging.

Figure 2 Patient magnetic resonance imaging of hepatobiliary phase and plain scan phase. A: Patient one’s magnetic resonance imaging (hepatobiliary phase); B: Patient one’s magnetic resonance imaging (plain scan phase); C: Patient two’s magnetic resonance imaging (hepatobiliary phase); D: Patient two’s magnetic resonance imaging (plain scan phase). The yellow marked area represents the regions of interest.

Figure 3 Receiver operating characteristic curve of relative enhancement ratio. Receiver operating characteristic curve analysis relative enhancement ratio was used to predict the efficacy of tyrosine kinase inhibitors combined with programmed death-1 in patients with advanced hepatocellular carcinoma (area under receiver operating characteristic curve = 0.874). ROC: Receiver operating characteristic.

Figure 4 Kaplan-Meier survival estimates of progression-free survival. A: Comparison of patients with relative enhancement ratio < 0.9 and relative enhancement ratio ≥ 0.9; B: Comparison of patients with neutrophil-to-lymphocyte ratio < 5 and neutrophil-to-lymphocyte ratio ≥ 5; C: Comparison of patients with platelet-to-lymphocyte ratio < 300 and platelet-to-lymphocyte ratio ≥ 300; D: Comparison of patients with prognostic nutritional index < 45 and prognostic nutritional index ≥ 45. RER: Relative enhancement ratio; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic nutritional index.